Autopsy report · NCT01609582
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Cause of deathSafety
“Due to potential concerns about liver safety (See Detailed Description)”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 3,207 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Takeda
- Sponsor type
- Industry
- Conditions
- Type 2 Diabetes; Cardiovascular Disease
- Interventions
- TAK-875; TAK-875 Placebo
- Participants
- 3,207
- Sites
- 584
- Countries
- Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Hungary and more
Trials that died the same way
- Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
“Hepatic safety signal identified.” - Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
“Due to a lack of safety and efficacy.” - Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
“Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.” - A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
“This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.